Constructing High-Yielding Serratia marcescens for (−)-α-Bisabolol Production Based on the Exogenous Haloarchaeal MVA Pathway and Endogenous Molecular Chaperones

This is the authors' abstract. We don't add key points for this paper.

(−)-α-Bisabolol exhibits analgesic, anti-inflammatory, and skin-soothing properties and is widely applied in the cosmetic and pharmaceutical industries. The use of plant essential oil distillation or chemical synthesis to produce (−)-α-bisabolol is both inefficient and unsustainable. Currently, the microbial production of (−)-α-bisabolol mainly relies on Escherichia coli and Saccharomyces cerevisiae as chassis strains; however, high concentrations of (−)-α-bisabolol have certain toxicity to the strain. This study uses synthetic biology and metabolic engineering strategies to redesign a solvent-tolerant Serratia marcescens for the efficient production of (−)-α-bisabolol. By introducing the Haloarchaea-type mevalonate (MVA) pathway and the (−)-α-bisabolol biosynthesis pathway, we successfully constructed a strain capable of producing (−)-α-bisabolol. The coexpression of the chaperone protein DnaK/J significantly enhanced the soluble expression of the (−)-α-bisabolol synthase, resulting in a 10% increase in (−)-α-bisabolol titer. Furthermore, knockout of the PhoA gene, which reduced the formation of the byproduct farnesol (FOH), further increased the (−)-α-bisabolol titer to 3.21 g/L. In a 5 L bioreactor, S. marcescens achieved a final (−)-α-bisabolol titer of 30.2 g/L, representing the highest titer reported to date. This research provides guidance for the production of (−)-α-bisabolol in nonmodel microorganisms without the requirement for induction.